Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 12, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,400,000 ordinary shares.
- Purchase Price: 1,180.1 pence per share.
- Treasury Holdings: 487,279,158 shares (representing 8.80% of total voting rights).
- Shares in Issue: 5,537,980,679 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback authorized by shareholders at the Annual General Meeting on May 23, 2007. This transaction increased the company's Treasury share holdings to 8.80% of total voting rights.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,537,980,679) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the updated Treasury share count (487,279,158) and its impact on voting rights (8.80%).
- Note that this filing is a regulatory disclosure of a share buyback and does not contain operational or financial performance data.